Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025
TD Cowen's 6th Annual Oncology Innovation SummitTuesday, May 27, 2025 at 9:00 a.m. PT (Virtual)
Management and Physician Presentation and Discussion of iMMagine-1 Pivotal Study Results During EHA2025Friday, June 13, 2025 at 8:30 p.m. CEST (Virtual and In-Person, Milan, Italy)
A live webcast of these discussions will be accessible from Arcellx's website at www.arcellx.com in the Investors section. A replay of the webcasts will be archived and available for 30 days following the event.
About Arcellx, Inc.
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx's mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. For more information on Arcellx, please visit www.arcellx.com. Follow Arcellx on X @arcellx and LinkedIn.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements, including Arcellx's expectations regarding the timing and outcomes of clinical trials for its product candidates and the potential impact of its product candidates and platforms on patients and cell therapy. The forward-looking statements contained herein are based upon Arcellx's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including risks that may be found in the section entitled "Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission (SEC) on May 8, 2025, and other documents that Arcellx files from time to time with the SEC. These forward-looking statements are made as of the date of this press release, and Arcellx assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250521064521/en/
Contacts
Investors: Myesha Lacyir@arcellx.com 510-418-2412
Media: Andrea CohenSam Brown LLCandreacohen@sambrown.com 917-209-7163
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
27 minutes ago
- Business Wire
Sammons Financial Group Employees Direct $175,000 to Iowa Charities
WEST DES MOINES, Iowa--(BUSINESS WIRE)-- Sammons ® Financial Group, Inc. announced the results of its 2025 Community Outreach Program. Sammons Financial Group employees selected 25 organizations to receive a total of $175,000 in financial support. Recipient charities were invited to the company's West Des Moines headquarters to further connect with employees about their organization and mission. The initiative, started in 2018, empowers employees to nominate their favorite local charities to be considered for a financial grant from Sammons Financial Group. The employees who choose to make nominations are given the opportunity to educate their coworkers on the mission of the organization and why they are passionate about it. Employees then vote for the organizations they would like the company to support financially. 'Our employees selected this year's recipients because of the excellent work they do in our community,' said Casey Decker, West Des Moines site leader and Chief Operating Officer at Sammons Financial Group. 'We're proud to support these organizations elevating the quality of life in Central Iowa.' The following organizations received funding from the 2025 Community Outreach Program: Aheinz57 American Cancer Society (Iowa Chapter) American Lung Association of Iowa American Parkinson Association Iowa Chapter Animal Rescue League of Iowa Building Brave Teams Camp Fire of Iowa Combat Vets Motorcycle Association Iowa Chapter 39-1 Des Moines Refugee Support Focuss Four Oaks Foster and Adoption Support Great Plains Pointer Rescue Hope Ministries Iowa Donor's Network Iowa Jobs for America's Graduates Kid Hope USA Leukemia and Lymphoma Society of Iowa Mason's Lighthouse Peace Creek Animal Sanctuary and Rescue SEEDS Shriner's Children's Hospital in partnership with Blank Children's Hospital Sleep in Heavenly Peace The Supply Hive Urban Bicycle Food Ministry Waypoint Resources The Community Outreach Program is one part of Sammons Financial Group's longstanding commitment to its communities. In 2024, the company donated $4.7 million to local charities through its various charitable giving programs. West Des Moines is home to about 1,000 on-site and remote employees. A similar program is held each year in the Sioux Falls office, which has 600 employees. About Sammons ® Financial Group, Inc. Sammons Financial Group ® helps families and businesses by empowering futures and changing lives. Sammons Financial Group is employee owned with member companies that are among the most enduring and stable in the financial services industry. Our member companies include Midland National ® Life Insurance Company (including Sammons ® Corporate Markets); North American Company for Life and Health Insurance ®; Sammons Institutional Group ® (including Midland Retirement Distributors ® and Sammons Retirement Solutions ®) and Sammons Wealth Management Group. Committed to our communities, Sammons Financial Group is Midwest-based, with offices in Iowa, Illinois, Minnesota, North Dakota, Ohio, and South Dakota.
CNBC
28 minutes ago
- CNBC
Meta shares fall on AI restructuring report, while Lilly shrugs off Novo's Ozempic price move
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Stocks aren't moving much Monday as Wall Street waits on retail earnings and a speech from Fed Chair Jay Powell later in the week. Monday's session lacks clear themes, but Meta Platforms stands out as a laggard after a report from The Information said the longtime Club holding is planning the fourth restructuring of its AI team in six months. The story is raising questions in light of Meta's significant investment in recruiting AI talent from other tech companies. Novo price cut : Shares of Club name Eli Lilly are relatively unchanged despite chief rival Novo Nordisk lowering prices for its popular GLP-1 medication. Novo Nordisk announced on Monday that it has cut the price of Ozempic, its popular GLP-1 for Type 2 diabetes, to $499 per month for cash-paying patients that use its NovoCare direct-to-patient program. Novo also announced that it has partnered with GoodRx to offer the same price for Ozempic and the weight-loss drug Wegovy at U.S. pharmacies. While the news may spark concerns that a price war is heating up in a battle for market share, we don't see this specific Ozempic development advancing that narrative. The main reason why is that the cash-pay market for GLP-1s to treat Type 2 diabetes is not as important as it is for their obesity counterparts. It all comes down to insurance coverage, which is much higher for these medications for diabetes than weight loss. Indeed, Lilly does not offer Type 2 diabetes treatment Mounjaro on its LillyDirect platform, while sister drug Zepbound for obesity is on there. Lilly executives were asked about this on the company's August earnings call, and the president of Lilly USA, Ilya Yuffa, had this to say: "With Mounjaro, we have significant coverage. So, over 90% coverage in both commercial as well as [Medicare] Part D. And so, we're not sure if [adding Mounjaro to LillyDirect] necessarily provides additional avenue. With Zepbound, we see significant growth because we do have coverage gaps in commercial. And obviously, we also have coverage gaps without having the ability to cover anti-obesity medications in Part D. So, we see this as an opportunity for us to meet that need. For what it's worth, we still like where Lilly sits in the obesity side of the GLP-1 market. Back in February, Eli Lilly announced that self-pay patients could get Zepbound single dose vials for $499 per month through its LillyDirect platform. That's on par with the price for Wegovy on NovoCare. Since head-to-head studies have found Lilly's Zepbound to be superior to Novo Nordisk's Wegovy on weight loss, patients should continue to prefer Lilly's GLP-1s. We initially downgraded our rating on Eli Lilly after its earnings a few weeks ago, partly due to concerns about a potential price war. However, we reversed course and upgraded the stock back to a buy-equivalent 1 following signs of confidence driven by significant insider buying activity. Nuclear win : Alphabet's Google and the nuclear energy company Kairos Power announced on Monday the deployment of an advanced nuclear plant to the grid. Per the agreement, a reactor operated by Kairos Power will deliver up to 50 megawatts of reliable, 24/7 energy to the Tennessee Valley Authority electric grid that powers Google data centers in Tennessee and Alabama. The electricity will come from Kairos' Hermes 2 plant, which is scheduled to begin operations in 2030. The collaboration underscores how hyperscalers are creating new partnerships with nuclear energy providers to secure, around-the-clock power supply toward the end of the decade. Unlike gas-fired electricity, nuclear power offers tech giants like Alphabet a way to run their data centers on clean energy while advancing their decarbonization goals. While Club name GE Vernova is probably best known for its heavy-duty gas turbines , the power generation company also makes small modular reactors that have gained in popularity, so nuclear developments are important to follow closely. Up next: Palo Alto Networks reports after the closing bell , the first of three Club stocks with earnings this week. Before the opening bell on Tuesday, we'll see earnings from Club name Home Depot , Medtronic , and Viking Holdings . On the data side, we'll see July housing starts and building permits, but we'll take are cue on the housing sector from what Home Depot management says on the earnings call. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Yahoo
31 minutes ago
- Yahoo
Prediction: Buying MercadoLibre Today Could Set You Up for Life
Key Points MercadoLibre is one of the world's fastest growing e-commerce companies. It has plenty of room to grow in Latin America. It still looks reasonably valued relative to its long-term growth potential. 10 stocks we like better than MercadoLibre › MercadoLibre (NASDAQ: MELI), Latin America's largest e-commerce company, went public at $18 a share in 2007. Today, its stock trades at about $2,330. That 12,844% gain would have turned a $10,000 investment into $1.29 million. From 2007 to 2024, MercadoLibre's annual revenue grew at a stunning CAGR of 38%. It established a first mover's advantage in Latin America's fertile e-commerce market, expanded its logistics network across the region's challenging terrain, and locked its shoppers into its Mercado Pago digital payments platform and other fintech services. MercadoLibre also turned profitable again in 2021, and its annual net income increased at a whopping CAGR of 184% over the following three years. Its profits surged as it sold more higher-margin products on its first-party marketplace, generated higher-margin revenue from its third-party marketplace, expanded its higher-margin credit and advertising segments, and leveraged its economies of scale to dilute its logistics, payment processing, and marketing expenses. Those growth rates are incredible, but some investors might be reluctant to buy MercadoLibre's stock after those multibagger gains. However, I believe buying MercadoLibre's stock today could still set you up for life for three simple reasons. 1. It hasn't saturated its core markets yet MercadoLibre operates its marketplace in 19 Latin American countries. However, it generates most of its revenue in Brazil, Argentina, and Mexico -- and it still has plenty of room to grow in smaller markets like Chile, Colombia, Peru, and Ecuador. At the end of 2024, MercadoLibre served more than 100 million annual unique active buyers and 60 million fintech monthly active users. But that's just a fraction of the 668 million people (including 451 million adults) who live in the Latin American and Caribbean region. Latin America's population is also expected to keep growing through 2050. That low penetration rate gives MercadoLibre plenty of room to expand its e-commerce and fintech platforms. Grand View Research expects Latin America's e-commerce market to grow at a CAGR of 16.7% from 2024 to 2030. IMARC Group predicts the region's fintech market will expand at a CAGR of 15.9% from 2025 to 2033. If MercadoLibre stays at the top of those booming markets, it will likely generate double-digit sales growth for the foreseeable future. 2. It's growing a lot faster than its overseas competitors From 2024 to 2027, analysts expect MercadoLibre's revenue and EPS to grow at a CAGR of 27% and 34%, respectively. That makes it one of the world's fastest-growing e-commerce companies. By comparison, analysts expect Amazon (NASDAQ: AMZN) and Sea Limited (NYSE: SE) -- which both tried in vain to challenge MercadoLibre in Latin America -- to grow their revenue at a CAGR of 11% and 21%, respectively, from 2024 to 2027. 3. It looks reasonably valued relative to its growth potential MercadoLibre's stock has already rallied nearly 40% this year, but it still doesn't seem too pricey relative to its e-commerce peers at 35 times next year's earnings. Amazon trades at 29 times forward earnings, while Sea trades at a higher forward multiple of 40. MercadoLibre's valuations are likely being compressed by the near-term concerns about tariffs, inflation, and political unrest across several of its top markets. The devaluation of Latin American currencies against the U.S. dollar (in which MercadoLibre reports its earnings) could be exacerbating that pressure. But if those headwinds eventually dissipate, MercadoLibre's stock could command a much higher valuation again. How much bigger could MercadoLibre grow? Assuming MercadoLibre matches analysts' expectations through 2027, grows its EPS at a robust CAGR of 20% over the following 18 years, and trades at a reasonable 30 times earnings by the final year, its stock price could potentially climb more than 30 times to $71,480 by 2045. That price target sounds high, but it would only boost its market cap to $3.6 trillion. For reference, Amazon currently has a market cap of $2.4 trillion -- and it will likely be worth a lot more in 20 years. Therefore, if you expect MercadoLibre to maintain its leading position in Latin America's e-commerce and fintech markets, expand its margins as it scales up its business, and weather the region's near-term macro headwinds, then it's still an excellent long-term buy. Should you invest $1,000 in MercadoLibre right now? Before you buy stock in MercadoLibre, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and MercadoLibre wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Leo Sun has positions in Amazon and MercadoLibre. The Motley Fool has positions in and recommends Amazon, MercadoLibre, and Sea Limited. The Motley Fool has a disclosure policy. Prediction: Buying MercadoLibre Today Could Set You Up for Life was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
